Gil Roth10.31.13
Phase I
Kamada reports preliminary pediatric diabetes data . . . read more
Phase II
e-Therapeutics starts trial of tramadol CR formulation . . . read more
Phase III
Teva gets approval for CHF trial . . . read more
Post-Approval
Hyperion begins UCD outcomes study . . . read more
Filings
Ariad suspends Iclusig marketing in U.S. . . . read more
Baxter submits Rixubis in EU . . . read more
Stem Cell Therapeutics gets Orphan status for tigecycline in AML . . . read more
Kamada reports preliminary pediatric diabetes data . . . read more
Phase II
e-Therapeutics starts trial of tramadol CR formulation . . . read more
Phase III
Teva gets approval for CHF trial . . . read more
Post-Approval
Hyperion begins UCD outcomes study . . . read more
Filings
Ariad suspends Iclusig marketing in U.S. . . . read more
Baxter submits Rixubis in EU . . . read more
Stem Cell Therapeutics gets Orphan status for tigecycline in AML . . . read more